[144] Xeris Biopharma Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Xeris Biopharma (XERS) reports a proposed sale under Rule 144 consisting of 15,500 common shares tied to restricted stock units granted by the issuer. The filing shows these shares were acquired on 06/04/2025 as Restricted Stock Units and have an aggregate market value of $121,055. The sale is scheduled approximately for 09/11/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ market. The company reports 161,480,367 shares outstanding, and the filer certifies they are not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: A routine insider sale notice for 15,500 RSU-derived shares valued at about $121k, appearing immaterial relative to outstanding stock.

The filing documents a Rule 144 notice for shares acquired as restricted stock units on 06/04/2025 to be sold via Morgan Stanley Smith Barney on NASDAQ around 09/11/2025. At an aggregate value of $121,055 versus 161,480,367 shares outstanding, this transfer represents a de minimis proportion of the float and does not, on its face, indicate a material change in ownership or control. No prior sales in the past three months are reported. The filer makes the standard representation regarding lack of undisclosed material adverse information.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure of RSU sale; procedural and conforms to Rule 144 requirements with standard certifications.

This Form 144 provides the statutory notice for the proposed sale of shares issued as RSUs. It names the broker, specifies acquisition and payment details, and includes the required signature representation about material information. The disclosure appears complete for Rule 144 purposes: acquisition method, dates, amount, broker, market, and share counts are provided. There is no indication of regulatory, litigation, or governance concerns disclosed within this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	15500	121055.00	161480367	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2025	Restricted Stock Units	Issuer			15500	06/04/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does XERS propose to sell under this Form 144?

The filing proposes sale of 15,500 shares of common stock originally acquired as Restricted Stock Units.

When were the securities acquired and when is the approximate sale date?

The securities were acquired on 06/04/2025 and the approximate date of sale is 09/11/2025.

Which broker is handling the proposed sale for XERS?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.

What is the aggregate market value and how many shares outstanding does the filing show?

Aggregate market value is reported as $121,055 and total shares outstanding are 161,480,367.

Does the filer report other sales in the past three months?

The filing states Nothing to Report for securities sold during the past three months.